Skip to main content
Terug
HAWPY logo

Haw Par Corporation Limited

Datakwaliteit: 100%
Overbought
HAWPY
OTC Healthcare Drug Manufacturers - General
€ 53,50
€ 0,00 (0,00%)
Marktkapitalisatie: 2,96B
Ook genoteerd als HAWPF OTC
Dagbereik
€ 53,50 € 54,44
52-Weeksbereik
€ 28,64 € 54,44
Volume
7
50D / 200D Gem.
€ 50,64 / € 46,09
Vorige Slotkoers
€ 53,50

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 11,3 0,4
P/B 0,7 2,9
ROE % 6,2 3,8
Net Margin % 115,4 3,9
Rev Growth 5Y % 12,5 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue grew 12,52% annually over 5 years — strong growth
Net margin of 115,43% shows strong profitability
Debt/Equity of 0,01 — conservative balance sheet
Generating 264,87M in free cash flow
P/E of 11,34 — trading at a low valuation
PEG of 0,95 suggests growth is underpriced

Groei

Revenue Growth (5Y)
12,52%
Revenue (1Y)-7,57%
Earnings (1Y)14,43%
FCF Growth (3Y)119,62%

Kwaliteit

Return on Equity
6,19%
ROIC1,14%
Net Margin115,43%
Op. Margin29,17%

Veiligheid

Debt / Equity
0,01
Current Ratio7,13
Interest Coverage44,05

Waardering

P/E Ratio
11,34
P/B Ratio0,69
EV/EBITDA33,54
Dividend Yield0,08%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -7,57% Revenue Growth (3Y) -1,25%
Earnings Growth (1Y) 14,43% Earnings Growth (3Y) 9,83%
Revenue Growth (5Y) 12,52% Earnings Growth (5Y) 24,11%
Profitability
Revenue (TTM) 226,29M Net Income (TTM) 261,22M
ROE 6,19% ROA 5,91%
Gross Margin 55,99% Operating Margin 29,17%
Net Margin 115,43% Free Cash Flow (TTM) 264,87M
ROIC 1,14% FCF Growth (3Y) 119,62%
Safety
Debt / Equity 0,01 Current Ratio 7,13
Interest Coverage 44,05 Dividend Yield 0,08%
Valuation
P/E Ratio 11,34 P/B Ratio 0,69
P/S Ratio 13,08 PEG Ratio 0,95
EV/EBITDA 33,54 Dividend Yield 0,08%
Market Cap 2,96B Enterprise Value 2,21B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 226,29M 244,82M 232,06M 182,09M 141,18M
Net Income 261,22M 228,27M 216,57M 148,32M 110,10M
EPS (Diluted) 4,72 4,12 3,92 2,68 2,00
Gross Profit 126,71M 134,09M 134,89M 98,57M 73,64M
Operating Income 66,02M 63,84M 64,01M 43,38M 24,70M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4,42B 4,28B 3,59B 3,65B 3,28B
Total Liabilities 126,80M 128,47M 117,18M 101,41M 72,09M
Shareholders' Equity 4,29B 4,15B 3,48B 3,55B 3,21B
Total Debt 44,26M 36,30M 28,48M 58,40M 1,52M
Cash & Equivalents 791,26M 745,78M 574,01M 334,27M 596,23M
Current Assets 897,97M 4,01B 3,28B 380,58M 642,08M
Current Liabilities 125,93M 127,66M 116,41M 100,50M 71,19M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#690 of 820
24

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026